Dublin OH Feb.03, 2021 — N8 Medical, Inc d/b/a N8 Biosciences, announced today that it has appointed Peter M. Allen to its board of directors effective February 7, 2021.
Mr. Allen has an impressive background as a senior healthcare executive across a variety of healthcare verticals with specific expertise in P&L management, business development, sales, marketing, distribution management, regulatory affairs, political lobbying, group purchasing, research and development, manufacturing, M&A integration, and new product/business launches. Most recently, Pete was the Executive Vice President of sourcing operations at Vizient (from 2010 to 2019), the largest group purchasing organization in the United States with over 3,500 employees. Prior to Vizient, Pete served as Vice President and General Manager of the infusion therapy division at Becton Dickinson (NYSE:BDX), a $650 million business unit. Pete also held numerous sales positions at Kimberly-Clark Healthcare, ultimately serving as Director of Global Strategic Marketing. Through his entire career, Pete has led growth transformations and built established, defendable market-leading healthcare companies.
“We are all pleased to welcome Pete as a new independent director to the N8 Board and especially value the deep experience and success that Pete has had in so many areas that are critical to N8’s development and success” said David J Richards, N8’s executive chairman. “We have worked with Pete over the past six months and his insights and guidance have been invaluable.”
“I am pleased to join the N8 Board of Directors” Mr. Allen commented, “N8’s compounds are very promising and potentially lifesaving, especially in light of the many existing and emerging pathogens that lead to medical device related infections. I look forward to working with my fellow directors and management to help the company achieve its goal of making a significant impact in reducing injury and death from these conditions”.
ABOUT N8 MEDICAL
N8 Medical, LLC (www.N8Medical.com), headquartered in Dublin, Ohio, is a privately-held biotechnology company developing a platform of anti-fouling surface-protected medical devices designed to have significant preventative life-saving clinical impact through reduction of complications associated with biofilm growth on the surfaces of medical devices. N8 Medical’s CeraShield™ technology is based upon novel compounds called ceragenins that are small molecule, non-peptide, functional mimetics of naturally-occurring antimicrobial peptides and kill bacteria and fungi by membrane disruption, leading to rapid cell death.
CAUTION: In Canada, the CeraShield™ Endotracheal Tube obtained Health Canada Investigational Testing Authorization and remains the subject of investigational testing regarding the safety of the CeraShield™ ETT. In the United States, the CeraShield™ Endotracheal Tube has not been granted marketing approval by the FDA and is not yet available for commercial sale. The statements in this release have not been evaluated by Health Canada or the FDA.